Stocks in Focus

Hankook Tire & Technology Up 6%... Shares Rise on Assessment of "Excessive Undervaluation" [Featured Stocks]

KIM YOON-JEONG
2026-06-09 09:31:24
[Edaily Reporter Kim Yoon-jung] Hankook Tire & Technology is trading higher in early trading. This is believed to be driven by investor sentiment following analysis from the securities industry suggesting that the stock is currently undervalued.

According to MP Doctor on the 9th, #Hankook Tire & Technology was trading at 71,050 won as of 9:23 a.m. today, up 4,050 won (6.04%) from the previous trading day.
On the same day, Daol Investment & Securities maintained its “Buy” rating and 100,000 won target price for Hankook Tire & Technology.
Yoo Ji-woong, an analyst at Daol Investment & Securities, stated, “Although the company’s stock price is excessively undervalued, with a relative return of -62.7% compared to the KOSPI since the beginning of the year, robust earnings are expected to continue through the second quarter of 2026.” He added, "If strong shareholder return policies are implemented—such as raising the Total Shareholder Return (TSR) to 35% by 2026 and paying the first interim dividend—a significant valuation re-rating is expected."
Daol Investment & Securities analyzed that, with the current stock price trading at a price-to-earnings (P/E) ratio of 6.6, there is ample room for further revaluation.
The firm also noted that earnings momentum remains strong. Analyst Yoo predicted, “Earnings momentum in the tire division is expected to remain strong in the second quarter,” adding, “The company’s unrivaled profitability among global tire manufacturers will be reaffirmed.”
For the second half of the year, the firm expects the start of operations at the Tennessee plant in the U.S. and the effects of anti-dumping duties in Europe to have a positive impact. He analyzed, “In Europe, the share of Chinese imports is only about 7%, so anti-dumping duties will be applied at a lower level compared to competitors.”
Additionally, Analyst Yoo assessed that while the increase in sales volume is not significant, the strategy of expanding profits through higher average selling prices (ASP) is continuing. He further projected that although prices of raw materials such as butadiene have rebounded since the beginning of the year, this could be offset by additional price hikes in the second half of the year.

Economy

Corporation

IT·Science

Economy

NEXTBIOMEDICAL CO., LTD., Which Made Its Mark Globally with NexPowder, Named a “KOSDAQ Rising Star” for the Second Consecutive Year

#NEXTBIOMEDICAL CO., LTD., a company specializing in innovative medical devices, has been named to the Korea Exchange’s “KOSDAQ Rising Star” list for the second consecutive year, once again demonstrat…
2026-08-19 10:02:44

Corporation

Celltrion, Buoyed by Direct Sales, Expands into Asia’s Pharm-Emerging Markets... Solidifies No. 1 Position and Prepares New Drugs

Celltrion(068270)Celltrion is strengthening its market dominance in Asia—a leading “Shinhung” (emerging pharmaceutical) market—by leveraging its unrivaled direct-to-market competitiveness. While its f…
2026-08-19 09:54:02

IT·Science

LGCHEM,LTD Begins Preclinical Trials for ‘GNV205,’ an Immunotherapy Drug Based on Genube Technology

# LGCHEM,LTD is set to begin preclinical research on “GNV205,” an antibody-cytokine fusion candidate acquired from the domestic biotech firm GenuV. The company plans to develop it as a next-gen…
2026-08-19 10:20:03